AdvisorShares Psychedelic... (PSIL)

NYSEArca: PSIL · Echtzeitkurs · USD

25.98

-0.09 (-0.35%)

Zum Schluss: Aug 19, 2026, 4:40 PM

-0.35% (1D)

Keine Daten verfügbar

Geld	n/a
Marktkapitalisierung	n/a
Umsatz (TTM)	n/a
Nettogewinn (TTM)	n/a
Beta	n/a
EPS (ttm)	n/a
KGV (TTM)	n/a
Forward-KGV	n/a
KBV (TTM)	n/a
KUV (TTM)	n/a
Earnings Date	n/a

Brief	26.89
Volumen	12,371
Ø Vol. (20D)	41,133
Eröffnung	25.67
Vortagesschluss	26.07
Tagesspanne	25.74 - 26.39
52-Wk Range	15.36 - 26.39
Analyst	n/a
Kursziel	n/a
Dividenden	n/a
Ex-Dividenden-Datum	n/a

Über PSIL

The fund is an actively managed ETF that seeks to achieve its investment objective by investing, under normal circumstances, at least 80% of its net assets (plus any borrowings for investment purposes) in securities of companies that derive at least 50% of their net revenue from or devote 50% of their assets to psychedelic drugs and derivatives that have economic characteristics similar to such securities. The fund primarily invests in publicly l...

[Mehr lesen]

Branche n/a

Sektor n/a

IPO Datum Sep 16, 2021

Mitarbeiter n/a

Börse NYSEArca

Tickersymbol PSIL

Vollständiges Unternehmensprofil

Finanzielle Entwicklung

Im Jahr undefined betrug der Umsatz von AdvisorShares Psychedelics ETF n/a, ein Anstieg von undefined% im Vergleich zum Vorjahr (n/a). Der Gewinn lag bei n/a, ein Anstieg von undefined %.

Finanzberichte

Nachrichten

vor 1 Monat · The Daily Upside

Eli Lilly to Pay up to $3.8B for AtaiBeckley in Big Pharma’s Latest Psychedelic Foray

The deal gives Eli Lilly access to a ⁠psychedelic-based nasal spray that studies show curbs treatment-resistant depression in a single dose.

vor 1 Monat · WSJ

The Race to Commercialize the World’s Most Powerful Psychedelic

An obscure psychedelic is drawing intense interest from the pharmaceutical industry. WSJ explores why companies are betting hundreds of millions of dollars on the therapeutic potential of a toad poiso...